AST-platelet ratio index cannot be used in the exclusion of significant fibrosis in chronic hepatitis B patients ( Author's Reply )

References (6)

1. Güzelbulut F, Sezikli M, Çetinkaya ZA, Yaşar B, Özkara S, Övünç AOK. AST-platelet ratio index (APRI) in the prediction of significant fibrosis and cirrhosis in patients with chronic hepatitis B. Turk J Gastroenterol 2012; 23: 353-8
2. Jin W, Lin Z, Xin Y, Jiang X, Dong Q, Xuan S. Diagnostic accuracy of the aspartate aminotransferase-to-platelet ration index for the prediction of hepatitis B-related fibrosis: a leading meta-analysis. BMC Gastroenterol 2012; 12: 14
3. European Association for the Study of the Liver. EASL clinical practice guidelines: Management of chronic hepatitis B. J Hepatol 2012; 57: 167-85
4. Lok AS, McMahon BJ. Chronic hepatitis B: Update 2009. Hepatology 2009; 50: 661-2
5. Ahn SH, Chan HL, Chen PJ, et al APPROACH Working Group Chronic hepatitis B: whom to treat and for how long? Propositions, challenges, and future directions. Hepatol Int 2010; 4: 386-95
6. Güzelbulut F, Çetinkaya ZA, Sezikli M, Yaşar B, Özkara S, Övünç AOK. AST-platelet ratio index, Forns index and FIB-4 in the prediction of significant fibrosis and cirrhosis in patients with chronic hepatitis C. Turk J Gastroenterol 2011; 22: 279-85.